Skin fibroblasts grown from three individuals with osteogenesis imperfecta (OI) 
Introduction
Osteogenesis imperfecta (01)1 is a remarkably heterogeneous disorder with phenotypes that range from lethal in the perinatal period to mild, virtually asymptomatic conditions (1, 2) . A variety of molecular defects have been found to cause OI, including gene rearrangements (3) (4) (5) (6) , point mutations (7) (8) (9) (10) , genomic deletions or splicing mutations that result in deletion of single exon sequences from the mature mRNA and thus the protein (1 1, 12) , mutations that alter the reading frame in the gene for either chain oftype I procollagen (I 3),2 and mutations 1 . Abbreviations used in this paper: 01, osteogenesis imperfecta. 2. Willing, M., D. H. Cohn, and P. H. Byers. 1990 . J. Clin. Invest. In press. that alter the amount of type I procollagen synthesized (14) (15) (16) .
The relationship between the nature of the mutation and the clinical phenotype is only beginning to be explored. It appears that large rearrangements are likely to be lethal ifthey are expressed, and that the effect of small deletions may be determined by their chain location and the domain in the chain affected. We now present evidence that suggests that substitutions for glycine in the triple-helical domain of proal(I) are not always lethal and that the phenotypic effects of such substitutions depend primarily on the nature of the substituting residue and its location in the chain.
Methods
Clinical summary Family 1. The proband was a 21-yr-old woman of normal height who was active in a variety of sports and had had several previous fractures. On examination she was noted to have light blue sclerae but no dentinogenesis imperfecta or bone deformity. Her mother and all three siblings also had light blue sclerae and had had occasional fractures. None had bone deformity, hearing loss, short stature, or dentinogenesis imperfecta. Dermal fibroblasts were grown from the proband and her mother with appropriate consent.
Family 2. The proband was the second child of healthy nonconsanguinous parents from a town of 10,000 inhabitants in Iraq. The pregnancy was uncomplicated; the child weighed 2.67 kg and was 16.5 in. long at birth. Apgar scores were 8 and 9. The x rays at birth were remarkable for wormian bones in the skull, gracile bones of the upper extremities, short, broad, and bowed femurs, and thin bowed tibias ( Fig. 1) . At 6 wk the child was bright and alert. There was a triangular appearance to the face and the sclerae were blue. There had been at least one long bone fracture since birth. Both the prior pregnancy and a subsequent pregnancy resulted in normal infants. At 3 yr of age her height was 281/4 in. and her weight was 7 kg, both below the third percentile. She had blue sclerae, opalescent dentin, and small, broken teeth. Her speech was normal and she was at least average in intelligence. She crawled up stairs and on and offfurniture but did not stand without support. She had bilateral tibial, femoral, and humeral bowing. X rays confirmed the multiple bowing and demonstrated generalized-osteopenia. Dermal fibroblasts were grown from skin biopsies of both parents and ofthe affected infant when the child was 6 wk old; all biopsies were taken with appropriate consent. Family 3. The proband was the second child of a nonconsanguinous couple whose first child was normal. Ultrasound performed early in the third trimester identified a fetus with extremely short and bowed limbs and minimal calvarial mineralization. Elective delivery at 34 wk was performed and the infant died upon delivery. The radiologic picture was diagnostic of 01 type II, the perinatal lethal form of OI. There are multiple wormian bones in the skull, the ribs are thin without evidence of previous fracture, the femurs are short and bowed, and the tibias are bowed.
cysteine (1,010 Ci/mM; both from Amersham Corp., Arlington Heights, IL) under conditions previously described (17, 18) . Medium and cell-layer proteins were harvested separately in the presence of protease inhibitors (17, 18) and concentrated by ethanol precipitation (30% vol/vol) after addition of carrier collagen (25 ,Ag/ml; Sigma Chemical Co., St. Louis, MO). Digestion of procollagen with pepsin (50 jug/ml; Boehringer Mannheim Biochemicals, Inc., Indianapolis, IN) was carried out for 2 h at 1 8°C in 0.5 M acetic acid adjusted to pH 2.0 with HCI. The reaction was stopped by the addition of pepstatin and lyophylization.
Characterization ofcollagen by SDS-PAGE Proa chains were separated under reducing conditions in 5% acrylamide slab gels containing SDS and 2 M urea (17, 19) ; collagens were separated in the same gels under nonreducing conditions. In some experiments proteins separated in one dimension were cleaved in the gel with cyanogen bromide and the resultant peptides were analyzed by electrophoresis in a second dimension gel (18) .
Determination ofthermal stability
Thermal stability of pepsin-digested procollagens was determined as previously described ( 17, 18, 20 mm; Whatman Laboratory Products Inc., Clifton, NJ) in the same buffer, and eluted with a 300-ml linear gradient from 0 to 100 mM NaCl (21) . Type I procollagen was dialyzed into 10 mM NH4HCO3 and lyophylized.
The methods for isolating the fragment ofthe triple-helical domain of the a 1(I) chain that contained the cysteine residue differed slightly with each mutation.
In the first family the type I procollagen was cleaved with pepsin, the cysteine residues in the a chains were modified with 4-vinyl pyridine (22) , and the chains were separated by reverse-phase HPLC (23, 24 In the second family the cysteines in the isolated proa chains of type I procollagen were reduced and carboxymethylated with iodoacetate after reduction for 4 h in 8 M urea with DTT. Sodium iodoacetate was added to a final concentration of 20 mM and after 15 min a fresh aliquot of DTT was added and the sample was dialyzed into 0.1 M acetic acid before lyophylization. The dried sample was digested with cyanogen bromide for 24 h and the resulting peptides were separated by reverse-phase HPLC (see below for details). The tubes that contained aI(I)CB3 were pooled and dried. Purified al(I)CB3 was cleaved at the single Asn-Gly bond in the peptide with hydroxylamine (25) . The sample was dissolved in water and warmed to 40°C, an equal volume ofcold 2 M NH2OH, pH 10.5, was added, and the mixture was incubated at 35°C for 90 min. The sample was then frozen before separation of the fragments. The new peptides were resolved by HPLC (see below) and the 35S-containing fragment was identified by liquid scintillation counting. The labeled fragment was dried and subjected to automated peptide sequence analysis. For the first eight cleavages 80% of the sample was committed to identification of PTH-amino acids and the remainder was monitored by liquid scintillation counting; the entire sample was counted for products of cleavages 9-29.
After purification of type I procollagen synthesized by the cells from the patient in family 3, the molecules were cleaved with pepsin and the cysteine residues in the a chains were reduced with DTT and alkylated with 4-vinyl pyridine. The chains were cleaved with cyanogen bromide and a I (I)CB7 was separated by reverse-phase HPLC. The peptide was then cleaved with trypsin and the fragment that contained 35S was isolated by reverse-phase HPLC and then subjected to sequence determination as above. samples from families 2 and 3 there was a band that migrated just slower than the normal al(I) (Fig. 2 B) . The amount ofthe abnormal band that remained within the cells differed among the three cell strains; there was virtually none in the cells from the proband in family 1 and increasing amounts in the probands from families 2 and 3, respectively. Localization ofthe new cysteine residues in aJ (I). To characterize the abnormal bands synthesized by cells from the probands, we separated the pepsin-treated [3H]proline-labeled collagenous proteins in the first dimension under nonreducing conditions, cleaved the proteins in the gel with cyanogen bromide, and examined the peptides in a second dimension gel under nonreducing and reducing conditions. When the peptides were separated under reducing conditions, in each case the band that migrated between al(I) chains and the (al [III)3 molecules gave rise to the peptides of al(I) (Fig. 3) . Under nonreducing conditions the expected peptides from the new chain synthesized by cells from the proband in family 1 were all present but the partial fragment al(I)CB5-8 was missing (residues 86-401; Fig. 3 A) , which suggested that the cysteine was in the domain of al(I)CB5.
Separation ofpeptides by HPLC
When the peptides from the al(I) dimer synthesized by the cells grown from the proband in family 2 were separated under nonreducing conditions all the peptides except al(I)CB3 were present and an additional band of about the size of a dimer of al(I)CB3 was evident (Fig. 3 B, left panel) . When the peptides were separated under reducing conditions in the second dimension, all the peptides of al(I), including al(I)CB3, wereseen ( Fig. 3 B, right panel) . This indicated that the abnormal molecules synthesized by the proband contained a cysteine residue in the domain of al(I)CB3 (triple-helical residues 402-551), a region from which cysteine is normally excluded. The electrophoretic mobility of al(I)CB7, al(I)CB8, and al(I)CB6 from the dimer were normal; that of al(I)CB3 was delayed. In contrast, the electrophoretic mobilities of al(I)CB8 and al(I)CB3 derived from the band that migrated slightly slower than al(I) were delayed, while those of al(I)CB7 and al(I)CB6 were normal. These findings suggested that in this cell strain overmodification extended over a longer domain in molecules that contained a single mutant chain than in molecules that contained two mutant chains joined by a disulfide bond.
To better localize the new cysteine residue in proband 2,
we separated [35S]cysteine-labeled a chains in the first dimension by SDS-PAGE, cleaved them in the gel with hydroxylamine, and separated the resulting peptides in the second dimension. The major cysteine-containing band migrated more slowly than al(I)CB7 (271 residues) and more rapidly than the partial cleavage fragment al(I)CB7-6 (463 residues; not shown). This placed the new cysteine residue in both the al(I)CB3 fragment (residues 402-551) and the large hydroxylamine fragment (residues 523-980) and located it between residues 523 and 551. When the peptides from the al(I) dimer synthesized by cells from the proband in family 3 were examined under nonreducing conditions all the peptides except for al(I)CB7 were identified (Fig. 3 C) . The peptides from the slowly migrating a1(I) chain all migrated more slowly than those from the normal chain except for al(I)CB6, the carboxyl-terminal peptide of the triple-helical domain. These results indicated that overmodification of the chains in abnormal molecules began in a 1(I)CB7 and extended to the amino-terminal end of the molecule and that the new cysteine was situated between residues 552 and 822. (Fig. 4) isolated and, although the levels were low, alanine in the second position, aspartic acid in the sixth position, and alanine in the eighth position could be identified. The placement of the radiolabeled proline residues and the directly identified residues confirmed the identity of the fragment and the isolation of [35S]cysteine at the fourth cycle and indicated that there had been a cysteine for glycine substitution at residue 526 of the triple-helical domain of the a (I) chain. C, Two tryptic peptides were identified for their full length during sequence analysis. The major sequence contained the residues in the triple helix of a 1(I) from 704 to 725 and the minor sequence was derived from 421 to 434 of the triple helix of a (I). All residues, including the modified cysteine at 718, were identified. Each residue in all three panels is identified by the single letter code: A, alanine; D, aspartic acid; E, glutamic acid; G, glycine; K, lysine; L, leucine; M, methionine; N, asparginine; P, proline; Q, glutamine; R, arginine; S, serine; V, valine; P*, hydroxyproline. major running sequence for the tryptic peptide. In the peptide sequences around the mutant site in families 2 and 3 the proline that preceeded the cysteine appeared to be fully hydroxylated considering the PTH amino acid yield.
Abnormal molecules have a low thermal stability. In all three cell strains in which there is a cysteine for glycine substitution, the type I procollagen molecules that contained two abnormal chains (as evidenced by the presence of interchain disulfide bonds) melted at lower temperatures than control molecules, but at higher temperatures than those molecules that contained only a single abnormal chain (Fig. 5) . In collagens synthesized by cells from proband 1, molecules that contained the disulfide bonded a I(I) dimer melted between 41 and 42°C, and the abnormal molecules that contained a single abnormal chain melted between 39 and 40°C; in those from proband 2, the dimer melted between 40 and 41°C, and the molecules that contained a single abnormal chain melted at -39.5°C; in those from proband 3, the dimer melted between 37 and 38°C and the molecules that contained a single abnormal chain melted at -37°C. In each instance the single mutant chain (cysteine labeled) in the abnormal molecules was susceptible to proteolysis at a lower temperature than the normal chain (proline labeled) that had become overmodified.
Discussion
We have identified three separate families in which the presence of a cysteine residue within the triple-helical domain of the proa 1 The marked clinical heterogeneity in 01 has been difficult, to explain clearly on the basis of biochemical findings. The mildest dominantly inherited form, OI type I, often results from mutations that alter the amount of normal type I procollagen secreted by cultured cells (14) (15) (16) . Rarely, it may result from deletion of all of a COLlAl allele (Willing, M. C., and P. H. Byers, unpublished observations), but more commonly appears to result from a variety of other mutations that affect the synthesis of proal(I) chains (14) (15) (16) , the incorporation of proa 1(I) chains into type I procollagen,2 the rapid intracellular degradation of abnormal type I procollagen molecules, or evidence of an altered sequence within the telopeptide domain of the a 1(I) chain (26) ; linkage of the phenotype to mutations in both COLlA1 and COL1A2 is consistent with these biochemical and molecular genetic findings (27, 28) .
In most instances the perinatal lethal form, 01 type II, results from substitutions for single glycyl residues within the triple helical domain of a 1 (I) or a2(I). These mutations appear to interfere with the formation of stable triple helix, delay secretion of molecules that contain mutant chains, alter the extent of posttranslational modification of all chains in molecules that carry a defective chain (17) , interfere with aminoterminal propeptide cleavage, and result in an abnormal structure of type I procollagen molecules that may affect fibrillogenesis (29) . In rare instances the 01 type II phenotype may result from mutations that result in deletion or insertion of coding material (3-6). Between these extremes lies a large group of individuals with 01, classified on clinical grounds as either 01 type III (progressive deforming) or OI type IV (dominantly inherited with non-blue sclerae and often accompanied by dentinogenesis imperfecta) and ranging in severity from mild to moderately severe (1, 2) . Relatively few mutations that produce these disorders have been identified. A 4-bp deletion near the 3' end of the coding region of the proa2(I) chain that altered the last 12 residues of the chain and prevented its assembly into type I procollagen molecules produced an OI type III phenotype in the homozygous state but had little phenotypic effect in the heterozygotes (13, 30) . Deletion of single exons encoding domains near the amino-terminal end of the triple helix of the proa2(I) chain (11) or near the center of the triple helix (31) have produced mild-to-moderate phenotypes, as has a substitution of arginine for glycine near the carboxyl-terminal end of the triple-helical domain of proa2(I) (32) . This list, however, emphasizes the difficulty in providing a cohesive understanding of the genotype-phenotype relationship in the mild-tomoderate 01 phenotypes.
We think that our findings in the three families studied here, in addition to the accumulation of mutations rapidly being identified, begin to help understand some aspects of the relationships between mutation and phenotype. It This end-rule or phenotypic gradient for mutations along the proal(I) chain probably depends on the nature of the substituting amino acid. We are aware, for example, that substitution of arginine for glycine at positions 391 (9) or 664 (10) results in a lethal 01 phenotype and that substitution for glycine by arginine at position 154 results in the 01 type III phenotype. 4 Inspection of the sequence motifs around the lethal and nonlethal cysteine for glycine substitutions (Table I) does not clearly identify specific domains which, when altered, produce lethal phenotypes. For example, the substitutions at 718 and 748 both disrupt the hexapeptide GlyProHypGlyProHyp and are lethal. The substitution at 988 substitutes a glycine that succeeds a potentially hydroxylatable prolyl residue and the substitution is in a region bounded by additional hydroxyproline residues. In contrast, the substitution at 904 is in a region entirely devoid of hydroxyproline and would ordinarily be considered a relatively loose triple-helical domain. The nonlethal substitutions at 94 and 175 are in regions that are not rich in hydroxyproline and would probably be considered intermediate in stability. The substitution at 526 succeeds a hydroxylatable prolyl residue and is embedded in a region of moderate hydroxyproline content; if hydroxyproline content alone determined the phenotype, then this would be considered a candidate for a lethal mutation. Given these considerations, it appears that the nature of the substitution and its location in the chain are the major determinants of the phenotypic outcome of a point mutation. Because cysteine residues in the triple-helical domains of fibrillar collagens, in contrast to other substitutions, have the potential for covalent interactions with other molecules within the cell and in the matrix, cysteine substitutions may differ in their effects from those of other residues.
The prolyl residues that preceded the new cysteines in the abnormal a1(I) chains synthesized by cells from the probands in family 1 (position 93) and family 3 (position 717) were hydroxylated. These observations suggest that prolyl 4-hydroxylase may recognize general context as well as specific sequence.
The stability to thermal denaturation ofthe chains in molecules that contained one mutant and one normal a1(I) chain were not equivalent and the first proteolytic cleavage appeared in the abnormal chain. The sequences around the mutation sites in each chain we characterized include basic residues that would be cleaved by the trypsin in the incubation mixture (Table I ). Our observations suggest that the conformation of the single mutant chain is altered more than that of the two normal chains and, further, that the disulfide bond created in molecules with two abnormal chains acts to stabilize those chains in a less available conformation.
Finally, the findings in family 2 have an additional important implication in that they confirm that the OI type III phenotype can result from dominant mutations that result in substitutions for glycine residues in the triple helix of the a 1(I) chain of type I collagen. Until 
